Metabolic & Cardiometabolic
PCSK9 inhibition (evolocumab/alirocumab) decreases major adverse cardiovascular events ~15-25% in high-risk/secondary-prevention populations
In plain terms: Do the injectable cholesterol drugs (PCSK9 inhibitors) actually prevent heart attacks and strokes?
Part of: 💊 PCSK9 inhibitors
Yes; large randomized trials show evolocumab and alirocumab cut major cardiovascular events ~15-25%, with the clearest benefit in high-risk and secondary-prevention patients.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Large randomised trials show evolocumab and alirocumab cutting major adverse cardiovascular events by roughly 15 to 25 percent, with network meta-analyses agreeing in acute coronary syndrome and established atherosclerotic disease. The benefit is clearest in secondary prevention; limb outcomes in peripheral artery disease remain uncertain.
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Kao G, Chen C, Zhang Y, Xu Y, Xu G 2025 · BMC Cardiovasc Disord | meta-analysis | supports | high | Network meta-analysis in acute coronary syndrome shows evolocumab and alirocumab reduce MACE alongside marked LDL-C lowering. |
| Raone L, Gritti V, Mandurino-Mirizzi A, Sparasci FM, Scotti V, Currao A, Colonna G, Ferlini M, De Luca L 2026 · Am J Cardiovasc Drugs | meta-analysis | supports | high | Network meta-analysis of PCSK9 inhibitors in established ASCVD finds significant reduction in major cardiovascular events versus standard therapy. |
| Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Murphy SA, Walsh E, Liu L, Verma S, Sattar N, Nicholls SJ, Lopez-Sendon J, Gouni-Berthold I, Tokgozoglu L, Blankstein R, Cyrille M, da Silva Lima GP, Giugliano RP, Sabatine MS, VESALIUS-CV Investigators 2026 · JAMA | RCT | supports | high | Primary prevention (high-risk, no prior MI/stroke, incl diabetes): evolocumab reduced first MACE vs placebo, extending benefit beyond secondary prevention |
| Bandukwala LM, Curley D, Bontinis A, Bontinis V, Shalhoub J 2026 · Ann Vasc Surg | meta-analysis | mixed | moderate | Systematic review in PAD: PCSK9i lower lipids and CV risk but limb-outcome evidence uncertain; benefit population/endpoint-dependent |
| Ariyanti D, Rayyan MIR, Shabri HA, Nurwahyudi N, Husniatama MD, Erisadana RN, Larasati S, Mustofa A, Faizah NN, Putranto JNE, Alkaff FF, Saputra PBT 2026 · Curr Med Res Opin | meta-analysis | supports | moderate | Meta-analysis in peripheral artery disease finds PCSK9 inhibitors reduce cardiovascular and limb events on top of statins. |
| Gaba P, O'Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Giugliano RP, Sabatine MS 2023 · Circulation | RCT | supports | moderate | Open-label extension: continued evolocumab/very-low LDL sustained lower CV event risk over ~5yr with no new safety signal; durable benefit |
| Sabatine, Giugliano, Keech, Honarpour, Wiviott, Murphy, Kuder, Wang, Liu, Wasserman, Sever, Pedersen 2017 · N Engl J Med. 2017 May 4;376(18):1713-1722 | RCT | supports | high | FOURIER (NCT01764633), randomized double-blind placebo-controlled, n=27,564 with established atherosclerotic CVD on statin therapy, median follow-up 2.2 years. The primary endpoint is NOT 3-point MACE: 'The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization' — 'evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92'. The hard 3-point composite is the KEY SECONDARY: 'The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke' — 'the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88'. Achieved LDL median 30 mg/dL. No component breakdown is readable at abstract grade, so this paper's cardiovascular-death result is not stated here. Funded by Amgen; four co-authors are Amgen employees. ↩ SUPERSEDED — pooled in the review above, counted once |
| Hamzah KA, Kurmasha YH, Abdrabo MF, Srour MF, Al-Shammari AS, Badi MHI, Shweliya MA, Jena N, Sattar Y 2026 · Int J Cardiol Cardiovasc Risk Prev | meta-analysis | supports | moderate | Meta-analysis of 6 studies (6059 PAD patients) found PCSK9 inhibitors lowered MACE (RR 0.76, 95% CI 0.60-0.97), major amputation (RR 0.38, 0.15-0.95), and MI (RR 0.63, 0.50-0.79) vs placebo; revascularization and all-cause mortality were not significantly reduced. |
| Kafol J, Fras Z, Novakovic M, Sperling LS, Cevc M, Krevel B, Kafol L, Kelenc A, Kepic K, Vrbinc K, Svarc M, Groselj U, Jug B 2026 · Lipids Health Dis | observational | mixed | moderate | National prospective registry of 1385 patients confirms trial-like LDL-C reductions with low MACE rates in real-world PCSK9-inhibitor use. |
| Schwartz GG, Steg PG, Szarek M, Bhatt DL, ODYSSEY OUTCOMES Investigators 2018 · N Engl J Med 2018 Nov 29;379(22):2097-2107 | RCT | supports | high | n=18,924 recent ACS; alirocumab cut MACE 15% (HR 0.85) and all-cause death (HR 0.85); independent agent confirms class effect; industry-funded |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.